Purpose: We present planning and early clinical outcomes of a study of intensity-modulated radiotherapy (IMRT) for locally advanced prostate cancer. Methods and Materials: A total of 43 patients initially treated with an IMRT plan delivering 50 Gy to the prostate, seminal vesicles, and pelvic lymph nodes, followed by a conformal radiotherapy (CRT) plan delivering 20 Gy to the prostate and seminal vesicles, were studied. Dose-volume histogram (DVH) data for the added plans were compared with dose-volume histogram data for the sum of two CRT plans for 15 cases. Gastrointestinal (GI) and genitourinary (GU) toxicity, based on the Radiation Therapy Oncology Group scoring system, was recorded weekly throughout treatment as well as 3 to 18 months after treatment and are presented. Results: Treatment with IMRT both reduced normal tissue doses and increased the minimum target doses. Intestine volumes receiving more than 40 and 50 Gy were significantly reduced (e.g., at 50 Gy, from 81 to 19 cm 3 ; p = 0.026), as were bladder volumes above 40, 50, and 60 Gy, rectum volumes above 30, 50, and 60 Gy, and hip joint muscle volumes above 20, 30, and 40 Gy. During treatment, Grade 2 GI toxicity was reported by 12 of 43 patients (28%), and Grade 2 to 4 GU toxicity was also observed among 12 patients (28%). With 6 to 18 months of follow-up, 2 patients (5%) experienced Grade 2 GI effects and 7 patients (16%) experienced Grade 2 GU effects. Conclusions: Use of IMRT for pelvic irradiation in prostate cancer reduces normal tissue doses, improves target coverage, and has a promising toxicity profile. Ó
Radiotherapy patients will from time to time be treated on another linac than originally planned due to service or logistical challenges. For patients treated with dynamic intensity modulated radiotherapy (IMRT), extra care should be taken to make sure the delivered dose remains as planned. Four linacs with the same type of dynamic multileaf collimator (MLC) were compared to find a general prediction of the potential dosimetric error caused by treating IMRT patients on another linac without recalculating the treatment plan. The MLC parameters, transmission and dosimetric leaf separation (DLS) were measured for all four linacs. The dynamic fields that were measured to find the DLS value were imported into the treatment planning system to compare the calculated and measured doses. Measured values of transmission and DLS were used directly in the calculations to obtain dose differences of less than 1% between the calculated and measured doses at the reference setup. The dosimetric discrepancy between the linacs was acceptable for all but one linac. Recalculation of the treatment plan therefore remains as standard procedure for this linac when a planned patient must switch linac during the course of treatment. The depth and field size dependences of the MLC parameters were also tested, finding dose differences of up to 4%.
To increase dose homogeneity within certain radiotherapy targets, we defined a partially wedged radiation beam as a beam with wedge modification in one part of the field only. Partially wedged beams may be beneficial in cases with curved surfaces inside parts of the beam only, where they may compensate for missing tissue and/or for variations in depth to the target region. Possible sites suitable for partially wedged beams include urinary bladder and tangential breast irradiation. Customized partially wedged beams were delivered applying dynamic collimation techniques. Two different linear detector arrays, a semiconductor diode array and an ionization chamber array, were used independently in the same standard water tank to verify that the partially wedged beams were delivered according to the definition. Dose calculations of partial wedge fields were implemented in our treatment planning system and compared with the measured dose distributions. We re-planned a representative treatment plan for both advanced urinary bladder cancer and tangential breast irradiation using partially wedged beams. For both patients the target dose homogeneity was improved, and the doses to surrounding critical normal tissues were reduced.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.